Viyash Q2 FY27: Consolidated PAT ₹84.7 Cr, ~16% Like-for-Like Growth as Margins Compress
PAT +331.89% YoY · revenue +133.01% · margins compressing
₹987.94 Cr
+133.01% YoY
₹84.65 Cr
+331.89% YoY
8.47%
+3.9pp YoY
₹1.74
Viyash Scientific (formerly Sequent Scientific) posted consolidated revenue of ₹987.94 Cr and PAT of ₹84.65 Cr for Q2 FY27, up 4.4% and 6.8% sequentially over Q1 FY27's ₹946.36 Cr/₹79.29 Cr. The headline YoY jump against our database's year-ago base (₹423.99 Cr revenue, ₹19.60 Cr PAT) looks explosive at +133%/+332%, but that comparison predates the Composite Scheme of Amalgamation that folded SeQuent Research, Viyash Life Sciences and several other group entities into the listed company under pooling-of-interest accounting. The filing's own restated year-ago column — ₹850.30 Cr revenue, ₹72.90 Cr PAT — is the real like-for-like base, putting organic YoY growth at a much steadier ~16.2% on revenue and ~16.1% on PAT (adjusted). That is roughly in line with, or modestly ahead of, management's FY27 guidance of 13-15% API segment growth, though this is a total-company read rather than segment-specific.
Q2 FY-2027 vs prior quarters
Margins moved the other way: operating margin (EBITDA/revenue, ex-other income) slipped to 16.7% from 18.85% in Q1 FY27 and from a restated 20.37% a year ago, even as net profit margin held roughly flat at 8.47% (vs 8.31% QoQ, 8.50% restated YoY) — tax and finance-cost ratios offset most of the operating squeeze. The compression traces mainly to cost of materials rising to 44.4% of revenue from 42.5% in Q1 FY27, plus a step-up in employee costs to 18.7% of revenue from 17.2%; part of that increase is the non-cash ESOP charge of ₹37.7 Cr this quarter (₹56.3 Cr for H1) under the new Scheme 2026 ESOP, following the February 2026 grant of 1.31 crore options.
The stock went into the print at ₹255.32, up 9.6% over the past month of trading.
For context: this is the highest quarterly PAT in the last 6 quarters on our records; PAT has now risen for 5 consecutive quarters; revenue is at a 6-quarter high.
What the summary numbers don't show
Consolidated basic EPS ₹1.74 vs ₹1.51 in Q1 FY27
FY27 overall API growth 13–15% double-digit; companion animal formulation targeting 20%+ expansion; EV acquisition (BioForLife Italy) to close next few months, 18–24 month registration cycle. ₹250–300 Cr capex this year. 1 billion revenue target by FY32 at 18% CAGR.
— This quarter: met
No street preview or consensus estimate specific to this quarter turned up in search — full-year FY27 consensus (revenue ~₹3,900 Cr, +14%) exists on aggregator sites but nothing quarter-specific, so vs-street is marked unknown rather than guessed. Management's own press release was not available in the context to cross-check framing. The quarter's corporate actions tie into the guided EV/companion-animal push: the BioForLife Italia S.r.l. acquisition (flagged in the prior concall as pending) completed on October 1, 2026 for the full equity stake, and the company incorporated a new Vietnam subsidiary on November 2, 2026, both consistent with the stated geographic and portfolio expansion plan. A Senior VP-HR change and a 2% stake sale by White Oak Capital occurred in the quarter but carry no direct read-through to the P&L.
W1
Whether operating margin recovers toward the 19-20% range seen in Q1 FY27 and the restated year-ago quarter, or the 16-17% level persists as the post-merger/post-ESOP baseline
W2
Like-for-like growth trajectory against management's guided FY27 API growth of 13-15% and companion-animal formulation growth of 20%+, tracked off the ~16% H1 like-for-like base
W3
Integration contribution and costs from BioForLife Italia (completed Oct 1, 2026) and the new Vietnam subsidiary in upcoming quarters
Clean digital filing, column headers unambiguous, arithmetic ties exactly on both statements. Consolidated PAT of ₹84.65 Cr includes NCI of ₹8.48 Cr (owners' PAT ₹76.17 Cr). No exceptional items this quarter vs a ₹1.70 Cr amalgamation-related exceptional loss in the restated year-ago quarter. Reported YoY comps vs our DB base (pre-merger ₹423.99 Cr revenue/₹19.60 Cr PAT) are inflated by the Scheme of Amalgamation (pooling-of-interest restatement effective 16-Dec-2025); the filing's own restated year-ago column (₹850.30 Cr revenue/₹72.90 Cr PAT) is the true like-for-like base.
Informational and educational content only. Not investment advice.